Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05300815 |
Other study ID # |
2022-117 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
March 2, 2022 |
Est. completion date |
July 31, 2022 |
Study information
Verified date |
June 2023 |
Source |
Youngstown State University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Dry Needling is an intervention that continues to gain widespread interest as a treatment
adjunct for various pathological conditions. With the increased use of dry needling in the
clinic, there comes a need for additional research to investigate the adverse events
associated with the use of dry needling. Informed Consent is a process that is legally
required in many states prior to the performance of a treatment intervention like dry
needling. It is important therefore to identify which of these adverse events should be
included in an informed consent process.
Description:
Over the past 10 years, there have been a great deal of studies that examined the application
of DN to varying pathological conditions. Some of the more recent studies involving the
application of DN for various conditions include: temporomandibular joint dysfunction (TMD),
post-stroke, plantar heel pain or plantar fasciitis, osteoarthritis, headache, fibromyalgia,
neck and shoulder pain, lateral epicondylagia, back pain, and hallux valgus. In addition to
studies that applied DN to specific pathological conditions, the effects of DN have also been
studied. DN has been shown to: improve spasticity and range of motion (ROM), improve
flexibility of muscles, myofascial trigger point pain, scar tissue, and neuromuscular
control.
As DN interest continues to expand and studies continue to show the feasibility of applying
DN to a wider range of pathological conditions, there is a need to understand the risks
related to the use of DN. Understanding the risks associated with DN will allow for
improvements in clinical decision making regarding whether DN is an appropriate choice for
the patient. Informed Consent (IC) is a means of respecting the autonomous preferences of
persons seeking health care or participation in research. One of the important elements of IC
is the need to be explicit and descriptive about the risks of treatment which include: the
nature of the risk, the probability the risk will occur, the severity of the risk, and the
proximity of the risk. These are important elements that would allow the patient to be able
to consider the risks to benefit ratio of a given intervention and will lead to making a
better informed decision regarding their own care. Without the risks being properly
identified for the intervention, the IC process could not be adhered to and the patient would
not be able to make a well-informed decision regarding their own care.
There have been no studies that have described how the risks associated with DN should be
incorporated during the IC process to drive patient-centered care and autonomy in decision
making. The purpose of this study will be to utilize a Modified Delphi framework to identify
expert consensus on which risks should be included in the IC process.